PureTech Health PLC PRTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
-
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
-
PureTech Health plc – Half-Year Report
-
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
-
PureTech Health: Notice of Half-Yearly Results
-
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
-
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
Trading Information
- Previous Close Price
- GBX 150.40
- Day Range
- GBX 150.63–156.20
- 52-Week Range
- GBX 139.00–238.50
- Bid/Ask
- GBX 153.60 / GBX 154.20
- Market Cap
- GBX 37.18 Bil
- Volume/Avg
- 307,180 / 525,065
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 26.21%
Company Profile
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 90
- Website
- https://www.puretechhealth.com
Comparables
Valuation
|
Metric
|
PRTC
|
KNSA
|
MNMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 217.71 | — |
Price/Book Value | 1.44 | 3.91 | 2.10 |
Price/Sales | — | 5.06 | — |
Price/Cash Flow | — | 69.35 | — |
Price/Earnings
PRTC
KNSA
MNMD
Financial Strength
|
Metric
|
PRTC
|
KNSA
|
MNMD
|
|---|---|---|---|
Quick Ratio | 3.64 | 2.84 | 5.81 |
Current Ratio | 3.68 | 3.57 | 5.92 |
Interest Coverage | −3.86 | — | — |
Quick Ratio
PRTC
KNSA
MNMD
Profitability
|
Metric
|
PRTC
|
KNSA
|
MNMD
|
|---|---|---|---|
Return on Assets (Normalized) | −21.98% | 2.27% | −35.50% |
Return on Equity (Normalized) | −33.43% | 2.73% | −49.83% |
Return on Invested Capital (Normalized) | −32.07% | 2.66% | −49.35% |
Return on Assets
PRTC
KNSA
MNMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cllrwrwvq | Tkz | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cnrqtng | Hngbh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cstclhkd | Qtlnjf | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Clfnwwry | Qprcntw | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Rbznbtntw | Qnpkv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xnwrgsrt | Jbf | $28.0 Bil | |||
| Moderna Inc
MRNA
| Lvkjxyjzc | Cxtz | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Dzqcqdsz | Mbqz | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dspzcks | Qfndpv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Svlxjlkb | Skbkm | $12.6 Bil |
United States